← All reports

Biotech & Longevity · week of 17 Aug – 23 Aug

Biotech & Longevity: 17 Aug – 23 Aug

Pressure climbed 3 points across the week, 63 to 66.

66

pressure at the week’s end, 0–100

+3

move across the week

6

editions published

135

sources read behind them

The arc · 6 days with a board

The band each day fell in.

No written analysis for this week

Everything on this page is measured from the week’s own boards and editions. The written read is added when the engine runs its report pass; a week without one still has its record.

What we said to watch

17 Aug Whether the large Congolese trial of the mismatched vaccine shows real protection. It was built against a different species of Ebola, and it is the only shot that exists - the alternative is fighting this outbreak with none.

The beat ended the week Moving fast.

18 Aug Watch whether US kindergarten vaccine coverage keeps falling next school year. That number, not the measles count, decides how big the following outbreak can get.

The beat ended the week Moving fast.

19 Aug EyePoint runs a second trial, LUCIA, before the end of the year. Capricor has a 22 August decision on a Duchenne filing rewritten around arm function instead of the heart. Both turn on the same question: which measured outcome a regulator will accept as proof.

The beat ended the week Moving fast.

20 Aug Watch for the full melanoma numbers when they are presented at a medical meeting. An approval, the trials in other cancers, and the rival programmes at Roche and BioNTech all rest on a press release for now.

The beat ended the week Moving fast.

21 Aug Watch the follow-up trials Ultragenyx now owes the regulator. The approval rests on how much cornstarch a child needs, not on how often their blood sugar crashes, and only the second number tells you whether the therapy actually works.

The beat ended the week Moving fast.

22 Aug Watch whether China tightens the hospital-run gene-editing trials that sit outside the usual company-sponsored route. Two children have now died in that kind of study, and it is where a lot of the field's earliest human work is being done.

The beat ended the week Moving fast.

The honest half. These are the markers the boards named at the time — kept on the record whether or not they turned out to matter.

The board on Monday, and the board at the end

Opened

17 Aug

Outbreak pressure 88
Vaccine policy 76
Getting the drug there 66
Buyout money 62
Evidence discipline 48
Approvals flowing 36

Ended

22 Aug

Gene-therapy safety 78
Ebola in Congo 86
Trial measurements failing 76
Cancer vaccines 66
Thin evidence on ageing 52
New approvals landing 37

Both boards exactly as they were written at the time — not a diff. The engine names the forces fresh every morning, so "The cheap-yen gap" on Monday and "Money leaving the dollar" on Friday may well be the same pressure under different words. Comparing the labels would measure the labels; comparing the two boards yourself is the honest version.

The week’s editions · 6

Biotech 22 Aug · 17 SRC

The immune cell that multiplies after 100, in a week spent at the far edge of life

Biotech 21 Aug · 18 SRC

The gene therapy that fixes a child's liver and leaves the family history alone

Biotech 20 Aug · 30 SRC

A cancer vaccine finally clears a phase 3, in a week of four approvals

Biotech 19 Aug · 27 SRC

One eye chart, a billion dollars: the week the yardstick decided everything

Biotech 18 Aug · 22 SRC

The switch, not the gene: a week spent on what a cell is allowed to read

Biotech 17 Aug · 21 SRC

The deadliest Ebola outbreak on record, and a vaccine built for the wrong virus

The same week, another beat

Everything World Finance Tech Mind & body Climate Space Biotech Money Sports Gaming Food Cyber